Literature DB >> 10941183

Transcriptional dysregulation in Huntington's disease.

J H Cha1.   

Abstract

Although the gene responsible for Huntington's disease was discovered in 1993, the pathogenic mechanisms by which mutant huntingtin causes neuronal dysfunction and death remain unclear. However, increasing evidence suggests that mutant huntingtin disrupts the normal transcriptional program of susceptible neurons. Thus, transcriptional dysregulation might be an important pathogenic mechanism in Huntington's disease.

Entities:  

Mesh:

Year:  2000        PMID: 10941183     DOI: 10.1016/s0166-2236(00)01609-x

Source DB:  PubMed          Journal:  Trends Neurosci        ISSN: 0166-2236            Impact factor:   13.837


  107 in total

1.  Strains of [PSI(+)] are distinguished by their efficiencies of prion-mediated conformational conversion.

Authors:  S M Uptain; G J Sawicki; B Caughey; S Lindquist
Journal:  EMBO J       Date:  2001-11-15       Impact factor: 11.598

Review 2.  Huntington's disease.

Authors:  S Davies; D B Ramsden
Journal:  Mol Pathol       Date:  2001-12

3.  Effects of intracellular expression of anti-huntingtin antibodies of various specificities on mutant huntingtin aggregation and toxicity.

Authors:  Ali Khoshnan; Jan Ko; Paul H Patterson
Journal:  Proc Natl Acad Sci U S A       Date:  2002-01-15       Impact factor: 11.205

4.  Glutamine/proline-rich PQE-1 proteins protect Caenorhabditis elegans neurons from huntingtin polyglutamine neurotoxicity.

Authors:  Peter W Faber; Cindy Voisine; Daphne C King; Emily A Bates; Anne C Hart
Journal:  Proc Natl Acad Sci U S A       Date:  2002-12-16       Impact factor: 11.205

5.  Therapeutic effects of cystamine in a murine model of Huntington's disease.

Authors:  Alpaslan Dedeoglu; James K Kubilus; Thomas M Jeitner; Samantha A Matson; Misha Bogdanov; Neil W Kowall; Wayne R Matson; Arthur J L Cooper; Rajiv R Ratan; M Flint Beal; Steven M Hersch; Robert J Ferrante
Journal:  J Neurosci       Date:  2002-10-15       Impact factor: 6.167

6.  A cell-based assay for aggregation inhibitors as therapeutics of polyglutamine-repeat disease and validation in Drosophila.

Authors:  Barbara L Apostol; Alexsey Kazantsev; Simona Raffioni; Katalin Illes; Judit Pallos; Laszlo Bodai; Natalia Slepko; James E Bear; Frank B Gertler; Steven Hersch; David E Housman; J Lawrence Marsh; Leslie Michels Thompson
Journal:  Proc Natl Acad Sci U S A       Date:  2003-05-01       Impact factor: 11.205

Review 7.  Huntington's disease: a decade beyond gene discovery.

Authors:  Penelope Hogarth
Journal:  Curr Neurol Neurosci Rep       Date:  2003-07       Impact factor: 5.081

8.  Structural characterization of transglutaminase-catalyzed cross-linking between glyceraldehyde 3-phosphate dehydrogenase and polyglutamine repeats.

Authors:  Margherita Ruoppolo; Stefania Orrù; Simona Francese; Ivana Caputo; Carla Esposito
Journal:  Protein Sci       Date:  2003-01       Impact factor: 6.725

Review 9.  Functional aspects of cellular microcompartmentation in the development of neurodegeneration: mutation induced aberrant protein-protein associations.

Authors:  Judit Ovádi; Ferenc Orosz; Susan Hollán
Journal:  Mol Cell Biochem       Date:  2004 Jan-Feb       Impact factor: 3.396

10.  A potent and selective Sirtuin 1 inhibitor alleviates pathology in multiple animal and cell models of Huntington's disease.

Authors:  Marianne R Smith; Adeela Syed; Tamas Lukacsovich; Judy Purcell; Brett A Barbaro; Shane A Worthge; Stephen R Wei; Giuseppe Pollio; Letizia Magnoni; Carla Scali; Luisa Massai; Davide Franceschini; Michela Camarri; Marco Gianfriddo; Enrica Diodato; Russell Thomas; Ozgun Gokce; S J Tabrizi; Andrea Caricasole; Bernard Landwehrmeyer; Liliana Menalled; Carol Murphy; Sylvie Ramboz; Ruth Luthi-Carter; Goran Westerberg; J Lawrence Marsh
Journal:  Hum Mol Genet       Date:  2014-01-16       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.